Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 4, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - March 4, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/4/15 - "Reduced-Viscosity Concentrated Protein Formulations" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIU, Jun; SHIRE, Steven J., filed on March 7, 2014, was made available online on February 19, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novartis AG. The following qu
3/4/15 - 99.5% of Tekmira Shareholders Vote in Favor of Merger
Tekmira Pharmaceuticals Corporation, a leading developer of RNAi interference therapeutics today announced the voting results from its Special Meeting of Shareholders held Tuesday, March 3, 2015, in Vancouver, B.C. Shareholders voted 99.5% in favor of the Agreement and Plan of Merger, dated as of January 11, 2015, with OnCore Biopharma, Inc. and
3/4/15 - Acceleron Issues Results from Its DART Study [Health & Beauty Close - Up]
Acceleron Pharma reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma. In a release, the Company noted that the preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology 2015 Genitourinar
3/4/15 - AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter and yearly 2014 financial results after market close on Monday, March 9th, 2015. AcelRx Pharmaceuticals, Inc
Release date- 03032015- ALLSCHWIL, SWITZERLAND- Actelion Ltd today announced the formal acceptance of the New Drug Application for selexipag by the US Food and Drug Administration. The NDA dossier for selexipag in the treatment of pulmonary arterial hypertension was submitted to the FDA on the 22nd December 2014. Jean-Paul Clozel, M.D. and Chief Ex
3/4/15 - Acucela to Hold 2015 Annual Meeting of Shareholders on June 8, 2015
Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that its 2015 Annual Meeting of Shareholders will be held on Monday, June 8, 2015 at Acucela s headquarters in Seattle,..
3/4/15 - Aerpio Therapeutics Announces Publication of Positive Results of Phase 1b/2a Clinical Trial of Novel Tie2 Activator, AKB-9778, for the Treatment of Patients with Diabetic Macular Edema (DME) TIME-1 Study
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for vascular disorders with an emphasis on diseases of the eye, today announced publication of positive results from the company s Phase 1 b/2a clinical study of lead clinical candidate, AKB-9778, a Tie2 activator. The TIME-1 clinical r
3/4/15 - African Pharmaceutical Directory 2015
Dublin- Research and Markets has announced the addition of the "African Pharmaceutical Directory 2015" directory to their offering. The market potential of the African pharmaceutical and biotechnology sector is enormous and business opportunities abound. If you need to source from, or sell to Pharmaceuticals, Biotechnology products, Biopharmaceutic
3/4/15 - Agendia's BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
IRVINE, Calif.& AMSTERDAM Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new data from an ongoing study indicates the BluePrint functional molecular subtyping assay more accurately identifies molecular subgroups and may be a better guide for neoadjuvant treatment than standard, lo
3/4/15 - Alirocumab shows promise as treatment to reduce LDL-cholesterol in Phase III study
By a News Reporter-Staff News Editor at Biotech Week A recently published clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe. The report, which is published in the J
3/4/15 - Allergan Secures FDA Approval of NATRELLE INSPIRA Round Gel-Filled Breast Implants [Health & Beauty Close - Up]
"The FDA approval of NATRELLE INSPIRA round gel-filled implants exemplifies our commitment to scientific innovation and to meeting the dynamic needs of plastic surgeons and their patients," said Scott Whitcup, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan. "In the past two years, Allergan has received
3/4/15 - Ampio Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., March 4 Ampio Pharmaceuticals, Greenwood Village, Colorado, has been assigned a patent developed by David Bar-Or, Englewood, Colorado, Raphael Bar-Or, Denver, and Richard Shimonkevitz, Larkspur, Colorado, for the "treatment of T-cell mediated diseases." The patent application was filed on Nov. 14, 2012. Written by Amal Ahmed; edi
3/4/15 - ANI Pharmaceuticals To Present At 27th Annual ROTH Conference
ANI Pharmaceuticals, Inc. announced today that it will present at the 27th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On March 9, 2015 at 11 AM PT, Arthur S. Przybyl, President and CEO, will give the Company's presentation, which is posted on the Investor section of ANI's website at ANI Ph
3/4/15 - Anika Therapeutics Appoints Dr. Glenn Larsen to its Board of Directors
By a News Reporter-Staff News Editor at Biotech Week Anika Therapeutics, Inc. announced that it has appointed Glenn R. Larsen, Ph.D., as a new independent member of its Board of Directors. Anika's Board of Directors has voted to nominate Dr. Larsen for election by the stockholders at the 2015 Annual Meeting. About Anika Therapeutics, Inc. Headqua
3/4/15 - Array Biopharma Inc. Files SEC Form 8-K, Current Report (Feb. 13, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on February 13, 2015. The SEC file number is 0001100412-15-000010.. A U.S. Securities and Exchange Commission filing is a for
3/4/15 - Array Biopharma Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals [Amend] (Feb. 17, 2015)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on February 17, 2015. The SEC file number is 0001193805-15-000208.. A U.S. Securities and Exchange Commission filing is a for
3/4/15 - Arrowhead to Present at 2015 Barclays Global Healthcare Conference
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead s president and chief executive officer Christopher Anzalone, Ph.D., will present at the 2015 Barclays Global Healthcare Conference on March 11, 2015 at 1:35 p.m. EST. Arrowhead Research Corporation is a...
ASTRAZENECA TO PARTICIPATE IN US FDA ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE AstraZeneca today announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on 14 April 2015 to discuss the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in P
3/4/15 - Barco adds 5MP display cleared for mammography viewing to its new LED line of diagnostic displays
Release date- 03032015- Kortrijk, Belgium- Healthcare imaging specialist Barco announces the launch of a new diagnostic display system: Nio 5 MP LED. 'The Nio 5 MP LED fits into Barco's new family of diagnostic display systems, featuring a clean and modern design and a smaller desktop footprint for more reading comfort,' comments Lynda Domogalla, V
3/4/15 - Bellicum to Report Fourth Quarter and Full Year 2014 Financial Results on March 11, 2015
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, will report fourth quarter and year-end 2014 financial results after the close of U.S. financial markets on Wednesday, March 11, 2015. Bellicum management will host a webcast and conference call at 5:00 p.
3/4/15 - BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe
BioClinica's eClinical technologies include: the Microsoft Office-Smart OnPoint CTMS; Express EDC; Trident IRT; predictive clinical supply Optimizer; and Compass, the risk-based intelligent monitoring solution. Martijn Princen, BioClinica's Head of European eClinical Sales, remarked, "The event gives us another window into the pressing needs of our
3/4/15 - Biologics, Biosimilars and Biobetters: Strategies for Nonclinical Safety Testing, New Webinar Hosted by Xtalks
By a News Reporter-Staff News Editor at Biotech Week This webinar will discuss new Biologics, Biosimilars, and Biobetters programs using case studies to illustrate strategy choices and the similarities and differences between each program. Join speakers Judith Newmark, Program Manager, Pharmacology/Toxicology/Ocular at Toxikon Corporation, and...
3/4/15 - Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa), to EMA, FDA and Health Canada
Release date- 03032015- Ingelheim, Germany,- Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency, U.S. Food and Drug Administration and Health Canada.1. 'The submissions for idarucizumab mark the first regulatory submissions for a specific reversal agent
3/4/15 - Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab)
Bristol-Myers Squibb Company today announced an approval of an additional indication for Opdivo by the U.S. Food and Drug Administration. Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Company Media:
3/4/15 - CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, is pleased to announce the appointment of Rong Chen MD, Ph.D. as Chief Medical Officer.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement